935P - Status of immune system as a prognostic factor in vulvar cancer patients

Date 27 September 2014
Event ESMO 2014
Session Poster Display session
Topics Vulvar and Vaginal Cancers
Presenter Ekaterina Nerodo
Citation Annals of Oncology (2014) 25 (suppl_4): iv305-iv326. 10.1093/annonc/mdu338
Authors E. Nerodo, G.A. Nerodo, E. Zlatnik, V. Ivanova, G. Zakora
  • Department Of Gynecology, Rostov Research Oncological Institute, 344037 - Rostov-on-Don/RU



The purpose of the study was comparative analysis of immune status in vulvar cancer patients in dependence on treatment outcome.


Immune system status was studied in patients with stage III vulvar cancer aged 45-80 years in remission state (50 patients) and with relapse (40 patients). The results of examination of 30 practically healthy women served as control.


Significant differences in the studied immune status parameters were observed between patients in remission and patients with relapses. Level of lymphocytes and monocytes in patients in remission was higher than that in patients with relapses (28,4 ± 1,4% and 5,0 ± 0,06 % in comparison with 21,2 ± 1,7% and 3,9 ± 0,03%). Functional activity of T-lymphocytes in blast-transformation reaction was statistically significantly higher in relapses than in remission. Mitogen-induced proliferative activity of T- and B-lymphocytes (assessed according to phytohemagglutinin- and lipopolysaccharide-stimulated cells) was in average by 15% lower in patients in remission than in healthy women, but statistically significantly higher than in patients with relapses. Stimulation indices in patients with relapses were twice lower than in patients in remission. Level of natural killer cells in patients in remission was significantly higher than in patients with relapses – 13,0 ± 1,2% and 0,17 ± 0,01х109/l and 8,9 ± 0,9% and 0,08 ± 0,04х109/l. Quantity of circulating immune complexes in patients with relapses was higher than in patients in remission.


Thus, development of vulvar cancer relapses is accompanied by statistically significant suppression of parameters of immune system and, consequently, immune system status determines therapy outcome.


All authors have declared no conflicts of interest.